drug: |
paliperidone
|
| Clinical class | atypical antipsychotic, neuroleptic |
| Action | dopamine type 2 and serotonin type 2 antagonist |
| Chemical class | benzisoxazole derivative |
| CSA schedule | none |
| DEA number | |
| NDC | |
| Routes of administration | oral (OROS®) |
| Associated with (substance-related)
|
disorders: none |
| Availability | prescription |
U.S. Preparations:
Invega™ (Janssen) FDA approved for treatment of
:
12.19.2006 schizophrenia
US
prescribing information 